Navigation Links
Convergence Pharmaceuticals Announces Start of Phase II Study for Cav2.2 Selective Blocker, CNV2197944 in Pain Associated with Post-Herpetic Neuralgia
Date:4/23/2013

CAMBRIDGE, England, April 23, 2013 /PRNewswire/ --

Convergence Pharmaceuticals Limited ("Convergence"), the company focused on the development of novel and high value analgesic medicines for the treatment of chronic pain, today announces that it has started a Phase II proof of concept study with CNV2197944 in pain associated with post-herpetic neuralgia (PHN). Convergence is conducting the development of CNV2197944 on behalf of Calchan Ltd.

The trial is a randomised double-blind, placebo controlled, phase II study to evaluate the efficacy and safety of orally administered CNV2197944 in patients with PHN. The primary endpoint of the trial is the effect of repeat oral dosing of CNV2197944 on the pain experienced in PHN, as measured by the Pain Intensity Numeric Rating Scale (PI-NRS), after three weeks, compared to baseline. The study is expected to conclude in 1Q2014.

Post-herpetic neuralgia (PHN) is a nerve pain due to damage caused by the varicella zoster virus (Shingles or Chicken Pox). Typically, the neuralgia is confined to a dermatomic area of the skin and follows an outbreak of the virus in the same dermatomic area. Injury to sensory nerves can cause excruciating pain, sometimes persisting for months or years.

CNV2197944 is a novel, small molecule, state-dependent calcium channel blocker, designed to selectively inhibit highly active Cav2.2 channels. Based on positive pre-clinical and clinical data already reported, it is believed that CNV2197944 will be an effective treatment for neuropathic pain with analgesic potential for a broad range of chronic pain conditions. Extensive safety and toxicology studies to support the clinical development of CNV2197944 have also been completed, which suggest an excellent margin of safety and tolerability. CNV2197944 is the only truly selective Cav2.2 blocker in clinical development and has the potential to be a first in class treatment for chronic pain.

'/>"/>

SOURCE Convergence Pharmaceuticals
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Convergence Pharmaceuticals Announces Successful Interim Data from Ground-Breaking Phase II Trigeminal Neuralgia Study
2. Eighth Annual WLSA Convergence Summit Focuses on Moving from Innovation to Adoption
3. ISIS Pharmaceuticals Initiates a Clinical Study of ISIS-SMN Rx in Infants With Spinal Muscular Atrophy
4. Immune Pharmaceuticals CEO to Chair BIO International Panel "Can Israel Become the Next Biotech Startup Nation?"
5. European Nuclear Medicine / Radiopharmaceuticals Market - Global Trends & Forecasts to 2017
6. Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance In The United States For Its Previously Announced Acquisition Of Obagi Medical Products, Inc.
7. Statement from the Cystic Fibrosis Foundation on Promising Phase 2 Clinical Trial Results of Kalydeco and VX-661 (Vertex Pharmaceuticals Inc.)
8. ADial Pharmaceuticals Announces Agreement With FDA For Phase III Trial Of AD04 For Alcohol Use Disorder In Patients Of Targeted Genotypes
9. Inovio Pharmaceuticals Universal H1N1 Influenza Vaccine Achieves Protective Immune Responses Comparable to Conventional Vaccine in Phase I Study
10. Savara Pharmaceuticals Initiates Phase 2 Clinical Trial of AeroVanc for MRSA Lung Infection in Cystic Fibrosis Patients
11. Vanda Pharmaceuticals to Announce First Quarter 2013 Financial Results on May 9, 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... FRANCISCO , July 1, 2015 ... market) is expected to reach USD 49,119.2 million by ... Research, Inc. Monitoring services is expected to remain the ... of USD 1,227.5 million in 2012, and an estimated ...      (Logo: http://photos.prnewswire.com/prnh/20150105/723757 ) , Browse ...
(Date:6/30/2015)... Scotland , July 1, 2015 ... joins Nu C ana team   ... ProTide technology to develop and commercialise a portfolio of ... Chris McGuigan as Chief Scientific Officer. ... ProTide technology. He is currently Professor of Medicinal Chemistry ...
(Date:6/30/2015)... , June 30, 2015 Velos, Inc., the ... continues to grow and add customers who receive Clinical ... the 62 CTSAs awarded by the National Institutes of ... management. This is among the largest such market shares ... in the CTSA community keeps growing as a result ...
Breaking Medicine Technology:mHealth Market Worth $ 49,119.2 Million By 2020: Grand View Research, Inc. 2mHealth Market Worth $ 49,119.2 Million By 2020: Grand View Research, Inc. 3mHealth Market Worth $ 49,119.2 Million By 2020: Grand View Research, Inc. 4mHealth Market Worth $ 49,119.2 Million By 2020: Grand View Research, Inc. 5Internationally Renowned Medicinal Chemist Professor Chris McGuigan Appointed as NuCana's Chief Scientific Officer 2Internationally Renowned Medicinal Chemist Professor Chris McGuigan Appointed as NuCana's Chief Scientific Officer 3Velos continues adding CTSA customers - 40% now use Velos products 2
... 2011 The Mobile Dog Heart Health Tour is heading ... health examinations at Dreher Dog Park. From 1 to 5 ... on-site heart screenings in a soundproof medical unit, as well ... (Photo:   http://photos.prnewswire.com/prnh/20110127/CG37759 ) Since early 2009, veterinarians ...
... Lotus Pharmaceuticals, Inc. (OTC Bulletin Board: LTUSD) ("Lotus" or ... of medicine and drugs in the People,s Republic of ... investor interest, the Company has obtained land price guidance ... wishes to provide additional details regarding its 2008 purchase ...
Cached Medicine Technology:Vets to Provide Free Dog Heart Checks in West Palm Beach 2Vets to Provide Free Dog Heart Checks in West Palm Beach 3Lotus Pharmaceuticals Provides Inner Mongolia Land Price Guidance from Cha You Qian Qi Government 2
(Date:7/1/2015)... ... July 01, 2015 , ... B. E. Smith, the only ... a national chief nursing officer recruitment for Capital Health in ... industry, B. E. Smith has recently placed more than 1,000 healthcare executives into organizations. ...
(Date:7/1/2015)... Carlsbad, CA (PRWEB) , ... July 01, 2015 , ... ... Eye Examination Kit (Peek) smartphone app to test eyesight was just as accurate as ... London School of Hygiene and Tropical Medicine is responsible for the development of the ...
(Date:7/1/2015)... ... July 01, 2015 , ... Northbound Treatment Services ... of Referral Relations. , Emily originally entered the behavioral healthcare industry as ... implemented unique academic curriculum for clients to engage in their educational journey while ...
(Date:7/1/2015)... Vancouver, British Columbia (PRWEB) , ... ... ... over 600,000 residents in the communities of southeast Alabama, southwest Georgia and ... its partnership with TelmedIQ as its primary secure text messaging and clinical ...
(Date:7/1/2015)... ... July 01, 2015 , ... Foot and Ankle Specialists ... Division ) participated in the annual Howard County Family Wellness Day event at Centennial ... and included wellness screenings, activities for children, free workout demonstrations, and more. Drs. ...
Breaking Medicine News(10 mins):Health News:Capital Health Retains B. E. Smith to Recruit New Chief Nursing Officer 2Health News:Capital Health Retains B. E. Smith to Recruit New Chief Nursing Officer 3Health News:New Research Shows Reliability of Peek Eye Testing Mobile App 2Health News:New Research Shows Reliability of Peek Eye Testing Mobile App 3Health News:Northbound Treatment Services Welcomes Emily Orrick as Director of Referral Relations 2Health News:Southeast Alabama Community Health System Chooses TelmedIQ to Meet Secure Text Messaging Challenges for Healthcare 2Health News:Foot and Ankle Specialists of the Mid-Atlantic, LLC Promotes Healthy Living 2Health News:Foot and Ankle Specialists of the Mid-Atlantic, LLC Promotes Healthy Living 3
... Queen,s University-led study do not have an influenza pandemic plan ... addition, key players were not involved in developing the plans, ... enough just to have a plan, you have to test ... in an emergency," says Dick Zoutman, Queen,s professor of Community ...
... , , WELLESLEY, Mass. ... campaign to build awareness of the continued use of asbestos in ... asking students across the United States to use their creativity ... "the largest manmade public health crisis in history" according to the Asbestos ...
... 10, 2010 Robert W. Mahley, MD, PhD, president ... Research!America,s 2010 Builders of Science Award. The award ... president, guiding its growth to become one of ... its groundbreaking basic science and substantial impact on ...
... Scientists working with mice identify delay in key brain ... report they,ve gained greater understanding of fragile X syndrome, ... brain circuitry of mice. , The researchers, whose findings ... Neuron , say they,re developing insights into why some ...
... , PUYALLUP, Wash. , Feb. ... stimulus and the American Recovery and Reinvestment Act became ... digital imaging and data management integration project with interoperability ... dividends for MINW patients even after the completion of ...
... towards Vancouver for the 2010 Winter Olympics, The Physiological ... with a special issue exploring the biological and environmental ... "When most people think about these games we ... said co-editor Mike White from the University of Birmingham, ...
Cached Medicine News:Health News:Nationwide Video Search Kicks off Ban Asbestos Campaign 2Health News:Nationwide Video Search Kicks off Ban Asbestos Campaign 3Health News:Nationwide Video Search Kicks off Ban Asbestos Campaign 4Health News:Gladstone's Robert Mahley to receive Research!America advocacy award 2Health News:Medical Imaging Northwest Completes Phase I of Its Healthcare IT Integration to Maintain Patient Care Improvements 2Health News:Medical Imaging Northwest Completes Phase I of Its Healthcare IT Integration to Maintain Patient Care Improvements 3Health News:Exploring the limits: Understanding the challenges facing Winter Olympic champions 2
... Level 1 enables hospitals ... patient monitors to a ... Our temperature monitoring disposale ... are superior in their ...
... The pause of a heartbeat. The bodys ... rhythmic breathing. These vital signs are yours ... DeRoyals line of Temperature Monitoring products helps ... information needed to provide the most comfortable ...
... a heartbeat. The bodys warmth beneath drapes. ... vital signs are yours to guard, measure, ... Temperature Monitoring products helps you do your ... provide the most comfortable and precise management ...
... The bodys warmth beneath drapes. The life-giving ... are yours to guard, measure, stabilize and ... products helps you do your job, giving ... most comfortable and precise management of your ...
Medicine Products: